1-8 of 8
Peter O'Gorman, MD PhD
Close
Sort by
Journal Articles

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group

Jose M. Moraleda, MD, Carmelo Carlo-Stella, MD, David Garcia-Bernal, PhD, Ruben Jara Rubio, MD, Enriqueta Andreu, MD, Eleonora Calabretta, MD, Alessio Aghemo, MD, Maribel Diaz-Ricart, Marta Palomo, PhD, Enric Carreras, MD PhD, Israel Vlodavsky, PhD, Massimo Iacobelli, Jawed Fareed, PhD, Pedro Castro, MD PhD, Sara Fernandez, MD, Clifton C. Mo, MD, Gerald L. Weinhouse, MD, Kenneth R. Cooke, MD, Robert J. Soiffer, MD, Rebecca M. Baron, MD, Peter O'Gorman, MD PhD FRCP, FRCPath, Gregory Yanik, MD, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–8.
https://doi.org/10.1182/blood-2020-141872
Published: 2020
Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 264.
https://doi.org/10.1182/blood-2018-99-118242
Published: 2018
Journal Articles

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Ciara Tierney, BSc, Despina Bazou, BSc, MSc, PhD, Giao Le, BA (Hons), MB BCh, MRCPI, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 3177.
https://doi.org/10.1182/blood-2018-99-110166
Published: 2018
Journal Articles

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones That Can Inform Therapeutic and Drug Development Strategies

Despina Bazou, BSc, MSc, PhD, Muntasir M Majumder, MSc, BPharm, Ciara Tierney, BSc, Sinead O'Rourke, BSc, Pekka Anttila, MD, Raija Helena Silvennoinen, MD PhD, Caroline A Heckman, PhD, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2018-99-115910
Published: 2018
Journal Articles

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Jacob Laubach, MD, Andrew J Yee, MD, Jacalyn Rosenblatt, MD, Jeffrey V Matous, MD, Charles M. Farber, MDPhD, Thomas H. Openshaw, MD, Rodrigo O. Maegawa, MD, Michaela L. Tsai, MD, Irene M. Ghobrial, MD, Giada Bianchi, MD, Bhupendra Rawal, MS, Heidi Dipietro, RN, Kristen Cummings, RN, John Harran, RN, Peter O'Gorman, MD PhD FRCP, FRCPath, Kathleen Scott, PhD, Kathleen Fitzpatrick, Jennifer Abovich, Hannah Baker, Alexandra Savell, BS, Joshua Hansen, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 1981.
https://doi.org/10.1182/blood-2018-99-116280
Published: 2018
Journal Articles

Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function

Matthew Ho, Jiye Liu, PhD, Alireza Kalbasi, PharmD, Takeshi Harada, MDPhD, Teru Hideshima, MD PhD, Paul Dowling, BSc, PhD, Yu-Tzu Tai, PhD, Li Zhang, MD, Kenneth Wen, BS, Ralph Mazitschek, Amanda McCann, Kenneth C Anderson, MD, Peter O'Gorman, MD PhD FRCP, FRCPath, Giada Bianchi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4429.
https://doi.org/10.1182/blood.V130.Suppl_1.4429.4429
Published: 2017
Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Peter O'Gorman, MD PhD, Michael E O'Dwyer, MD, Oonagh Gilligan, MD, John Quinn, MD PhD, Mark Coyne, MD, Janusz Krawczyk, MD, Philip T Murphy, MD, Lourdes del Rosario McAlester, Orna Harraghy, Orlaith Cormican, Elizabeth Lenihan, Keith Egan, Meegahage Ratnakanthi Perera, MD, Gerard Crotty, Patrick J Hayden, MD, Brian Hennessy, MD MRCPI, FRCPath, Hilary M O'Leary, FRCPath, Kathleen Scott, PhD, Imelda Parker, PhD, Michele Cunnane, Jacinta Marron, Aoife Connell, Elizabeth Coghlan, Jacob P. Laubach, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2016) 128 (22): 2117.
https://doi.org/10.1182/blood.V128.22.2117.2117
Published: 2016
Journal Articles

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma

Kay Reen Ting, MB Bch BAO, Abdul Hameed, MBBS, MRCP, Jennifer Brady, Paul Dowling, PhD, Colin Clarke, PhD, Justine Meiller, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, Peter O'Gorman, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1869.
https://doi.org/10.1182/blood.V122.21.1869.1869
Published: 2013